The current financial score of MaxCyte Inc is 6.36. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 7.27M, representing a year-over-year decrease of 14.53%, while its net profit experienced a year-over-year decrease of 28.19%.
The current valuation score of MaxCyte Inc is 7.96. Its current P/E ratio is -3.26, which is -51.51% below the recent high of -1.58 and -680.37% above the recent low of -25.41.
The current earnings forecast score of MaxCyte Inc is 8.67. The average price target is 4.11, with a high of 5.00 and a low of 2.43.
The current price momentum score of MaxCyte Inc is 4.36. Currently, the stock price is trading between the resistance level at 1.36 and the support level at 1.08, making it suitable for range-bound swing trading.
The current institutional shareholding score of MaxCyte Inc is 7.00. The latest institutional shareholding proportion is 74.61%, representing a quarter-over-quarter decrease of 0.07%. The largest institutional shareholder is James Simons, holding a total of 1.91M shares, representing 0.00% of shares outstanding, with 112.96% increase in holdings.
The current risk assessment score of MaxCyte Inc is 2.80. The company's beta value is 1.21. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.